Use Cases
For healthcare, supply chain, and research organizationsArtifacts VERIFY delivers actionable information to prevent SF drugs from reaching patients
Partners
- Academic Research Partner: The Lieberman Lab at the University of Notre Dame with its research scientists, collaborators in Africa and East Asia, and Distributed Pharmaceutical Analytical Laboratories (DPAL) network of university laboratories
- Commercial Laboratory Partners: Artifacts VERIFY secures contracts with independent, certified commercial laboratories based on customer requirements
Performance
- Multi-tenant architecture maintains customer data privacy
- Dashboards display actionable intelligence and reporting that informs mitigation steps
- Blockchain encryption permanently secures data for audit compliance and chain of custody confirmations
- AWS service levels adapt as client load fluctuates to deliver reliable system responsiveness
Proposals
- Early-adopters who propose “at scale” projects will receive favorable terms and arrangements for subscription licenses
- Scientific research teams are encouraged to submit proposals for academic licenses
How the Lieberman Lab at Notre Dame uses Artifacts VERIFY to identify SF drugs
Pharmaceutical samples are obtained and screened for quality and safety from hospitals, clinics, and pharmacies in the sub-Saharan Africa region
Samples tested with PADs are forwarded to the Lieberman Lab for further analysis
Chemical assays are performed by a network of university laboratories in North America and Europe
Results of these analyses are immediately available in Artifacts VERIFY for scientific analysis and reporting to healthcare providers and regulatory authorities
Research projects in which Artifacts VERIFY is being used
Antibiotics
Incorporating Verify into an ongoing multi-year effort accelerates access to and visibility of results for the scientists and national government agencies in Sub-Saharan Africa engaged monitoring the quality of medicines that are distributed by pharmacies.
Chemotherapy Medicine
The high expense, stringent handling requirements, and emerging shortages of these drugs are factors driving a longterm research program among collaborators in Cameroon, Ethiopia, Kenya, and Malawi to assess the safety of medications administered in hospitals and clinical settings.
Contaminated Opioids
The epidemic of contaminated opioids is driving the design of a research program that will monitor drug contaminants and inform the development of prevention and treatment services.
Organizations interested in Artifacts VERIFY
Healthcare and Philanthropic Organizations
Artifacts VERIFY Objectives
Deepen relationships with existing collaborators
Expand monitoring of APIs among Low and Middle Income Countries (LMICs)
Identify partners in developed markets where drug safety concerns are emerging
Supply Chain Management Providers
Artifacts VERIFY Objectives
Provide analytics to support real-time mitigation activities
Reduce financial and operational risks for manufacturers
Complement existing technologies that monitor drug safety
Scientific Research Organizations
Artifacts VERIFY Objectives
Build an integrated global data resource for scientists, policy-makers, providers and patients
Provide insights into the incidence of SF drugs by drug type and geography
Advance development of innovations that identify SF medicines
Learn how to protect patients, brand reputation, and intellectual property from SF medicines
Learn how to protect patients from SF medicines